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Crohn Disease (CD) is a complex genetic disorder for which more than 140 genes have been identified 
using genome wide association studies (GWAS). However, the genetic architecture of the trait remains 
largely unknown. The recent development of machine learning (ML) approaches incited us to apply 
them to classify healthy and diseased people according to their genomic information. The Immunochip 
dataset containing 18,227 CD patients and 34,050 healthy controls enrolled and genotyped by the 
international Inflammatory Bowel Disease genetic consortium (IIBDGC) has been re-analyzed using a 
set of ML methods: penalized logistic regression (LR), gradient boosted trees (GBT) and artificial neural 
networks (NN). The main score used to compare the methods was the Area Under the ROC Curve (AUC) 
statistics. The impact of quality control (QC), imputing and coding methods on LR results showed that 
QC methods and imputation of missing genotypes may artificially increase the scores. At the opposite, 
neither the patient/control ratio nor marker preselection or coding strategies significantly affected the 
results. LR methods, including Lasso, Ridge and ElasticNet provided similar results with a maximum 
AUC of 0.80. GBT methods like XGBoost, LightGBM and CatBoost, together with dense NN with one 
or more hidden layers, provided similar AUC values, suggesting limited epistatic effects in the genetic 
architecture of the trait. ML methods detected near all the genetic variants previously identified by 
GWAS among the best predictors plus additional predictors with lower effects. The robustness and 
complementarity of the different methods are also studied. Compared to LR, non-linear models such as 
GBT or NN may provide robust complementary approaches to identify and classify genetic markers.
Crohn Disease (CD) is an inflammatory bowel disease (IBD) characterized by a chronic or relapsing inflamma-
tion of the gut with a prevalence of at least 0.1% in most developed countries1. It has been extensively studied 
by several groups, often in the context of the International IBD Genetics Consortium (IIBDGC), thus sharing 
common datasets and allowing comparisons between different approaches.
CD is a complex genetic disorder caused by multiple genetic and environmental factors. A major goal of med-
ical genetics is to accurately predict CD from these genetic and environmental parameters. In practice, we need 
to know risk factors, their effect sizes and how they interact. Environmental risk factors remain largely unknown, 
except cigarette smoking which is associated with a two-fold increased risk. In comparison, many common poly-
morphisms that are associated with IBD risk in the population have been identified up to date. Now, the question 
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is to know how they can be used to predict an individual’s genetic risk. “Genetic architecture of a disease refers 
to the number of genetic polymorphisms that affect the disease risk, the distribution of their allelic frequencies, 
the distribution of their effect sizes and their genetic mode of action (additive, dominant and/or epistatic)2”. 
More than 200 IBD associated loci have been recognized up to date3,4. Except for special clinical situations (like 
very early onset IBD), rare alleles with large effects (Odds Ratio (OR) > 2) have rarely been detected despite high 
throughout sequencing methods applied to a large number of patients5,6. Most associated variants are common 
with minor allele frequency (MAF) > 0:01) and risk alleles are either the minor or the major alleles. Their effect 
sizes are usually small (OR < 1:5) and often smaller (from 1:1 and to 1:2). For most of the identified polymor-
phisms, the genetic mode of action is multiplicative on the risk scale. Some SNPs have been specifically associated 
to CD in smokers7. However, despite this huge knowledge, the genetic architecture of the traits remains largely 
unknown as supported by the fact that we explain today only 13% of the genetic variance deduced from twin and 
family studies3,4.
Until now the genomic information has mainly been exploited on the basis of single-locus statistical analyses. 
However, this approach is under-powered to detect variants carrying low marginal effects alone but strong effects 
in association with other ones. The phenomenon that the effect of one variant depends on additional variants 
elsewhere in the genome is known as epistasis or genetic interaction. In case of strong genetic interaction, because 
only a combination of variants allows predicting the individual risk, the goal of geneticists is to find a risk equa-
tion combining presence/absence of each genetic variant to provide personalized predictions. Detecting genetic 
interaction would also greatly improve the explained genetic variance. However, optimal methods for selecting 
and combining SNPs remain to be developed.
Several methods have been proposed to analyze whole genotyping datasets looking for genetic interactions 
(for a review and their application to CD see8,9). A search for specific pairwise gene-gene interactions of known 
genetic factors was initially performed using statistical methods but it failed to identify genetic variants with 
strong interactions10,11. Genome-wide scans looking for two-loci interactions also failed to identify statistically 
significant epistatic effects8,12. Standard methods applied to higher orders of interactions were quickly limited 
by the multi-testing issue, the size of the datasets and computing power. For these reasons, more sophisticated 
machine learning (ML) methods have been proposed in order to capture the whole information of GWAS datasets 
using a direct pan-genomic approach. To explore the performances of different methods, the receiver operator 
characteristic (ROC) curve and its maximum Area Under Curve (AUC) are often used to compare the sensitivity 
and specificity of genetic tests in correctly classifying affected and unaffected individuals2.
The prediction of a specific phenotype such as “CD” or “non-CD” from raw genomic data such as SNPs can 
be thought in the framework of supervised learning as a binary classification problem. During training, the algo-
rithm learns from a genotyping dataset and adjusts its internal parameters to minimize an error cost function 
between predicted probabilities of phenotypes and actual patients phenotypes. After training, the performance 
of the system is measured on another set of a completely new case/control sample, to evaluate the generalization 
ability of the proposed algorithm.
Linear ML methods including multivariate logistic regression (LR) and sparse penalized methods such as 
Lasso have been proposed to identify disease associated SNPs13. Penalized methods perform two main tasks in 
the same process. First, it identifies a set of SNPs involved in disease prediction. Second, it calculates a weight for 
each SNP which reflects its contribution to the general model. Using the Welcome Trust GWAS dataset, Abraham 
et al. showed that penalized models achieved better performance than non-penalized methods even if the maxi-
mum AUC was no more than 0.7613. Using either GWAS datasets and/or Immunochip datasets, Chen et al. found 
an AUC of 0.8014. Wei et al. applied a LR with L1 penalty to the Immunochip dataset and obtained an AUC of 
0.8615. The observed differences are likely explained by the different datasets used and the quality controls (QC) 
applied13,14.
Penalized or non penalized LR are not suited to capture non linear interactions between loci because they 
only capture additive risk contributions. A non-linear model achieving better disease prediction results (in term 
of AUC score in our case), would allow to evaluate the amount of extra-information related to such interactions 
and provide some hint about their nature. To explore non linear interactions, ensemble tree-based methods such 
as random forest and gradient boosted trees (GBT) have been proposed8,16,17. In these methods, which are often 
providing state-of-the art results for structured datasets, ensembles of decision trees are trained to minimize the 
prediction error. Single trees, random forest and Bayesian models have been applied to CD with reported AUC in 
the same range or lower than penalized LR methods8,15,18–20.
Besides ensemble tree-based methods, other tools can be used to capture non-linear interactions. In particu-
lar, artificial neural networks (NN) are a powerful class of algorithms to learn non-linear relationships between 
an input - here the genotype - and a target variable - here the CD phenotype. Despite a long history, this class of 
algorithms has recently emerged in the framework of deep learning as a state-of-the-art solution to solve major 
artificial intelligence problems such as image classification, speech recognition or text translation21, relying on 
“signal-type” unstructured data.
Compared to tree-based methods, NN enable to build hierarchical internal representations of the data. Each 
neuron treats the information from several inputs (like the presence or not of a specific allele) and produces 
an output which is itself used by another neuron in the following layer. This structure draws multiple levels of 
representation. Starting from the raw inputs, it forms non-linear combinations of the initial features, each one 
providing a new representation of the initial data. By adding deeper layers, the networks build higher levels 
of abstraction and complexity which could be interpreted as biological functions. Deep network are known to 
amplify relevant inputs and lower the noise in data like images and sounds. However, the application of these 
approaches to standard tabular datasets does not generally outperform ensemble tree-based methods and it 
remains an open challenge to design efficient deep learning systems for this type of data. Despite its ability to 
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explore intricate structures in high-dimensional data22,23, to our knowledge it has rarely been applied to popula-
tion genetics and GWAS datasets24.
IIBDGC has collected a large dataset from CD patients and healthy controls genotyped for more than 150 
thousands genetic variants - mainly single nucleotide polymorphisms (SNPs)- forming the Immunochip panel3,25. 
Using this dataset, we first explored the impact of QC methods, allele coding strategies and marker selections 
on the test accuracy of Lasso as the reference method. Second, we applied a panel of different penalized logis-
tic regression, GBT and NN methods. Finally, we explored the robustness of the three approaches and their 
complementarity.
Methods
All methods have been carried out in accordance with relevant guidelines and regulations. All participants gave a 
written informed consent. The study has been approved by all the relevant national ethic committees as previously 
reported3.
Data pre-processing. The original cohort consisted in a total of 51951 people of mainly European descent 
(22208 males and 30069 females), divided as 18227 Crohn disease (CD) cases and 34050 controls. DNA samples 
were genotyped for the set of autosomal variants defined in the custom Illumina Infinium chip25. Genetic variants 
consisted in biallelic SNPs and a few small insertion deletions polymorphisms25. 156499 variants survived after a 
first QC performed according to the international consortium3. The density of the variants was not uniform along 
the genome, as previously reported14 (Fig. S1), genetic variants previously associated to immune disorders being 
over-represented25.
In the following we call A the major allele and a the minor one at a given site. Due to the biallelic nature of 
SNPs under study, in the dataset we substituted them by numerical values 0 and 1, and call NSNP the number of 
SNPs.
Quality control and imputation. It is well known that QC and imputation on GWAS data are delicate 
pre-processing steps for any genotype-phenotype association analysis, and that they can strongly affect results 
and biological interpretation26–28. Since one of the aim of this paper is to compare different ML approaches to the 
classification case-control problem, we first addressed the question of the impact of such an issue, on the AUC 
scores and on the interpretability of the feature importance selection.
In particular, for this part of the analysis, we have considered two cases:
NoQC - All samples and SNPs are kept for the analysis.
QC - The IIBDGC dataset is pre-processed by applying the cuts on samples and SNPs missing rates as in3. In 
particular, after excluding samples with missing SNP rate greater than 5%, SNPs with sample missing rate greater 
than 2% and with Hardy-Weinberg equilibrium (HWE) p-value < 10−10 in controls, we are left with 17966 CD 
cases, 33985 controls, for 146237 SNPs.
Moreover we proposed three different schemes to treat unknown genotypes in the dataset (notice that more 
sophisticated algorithms devoted to imputation, like for example IMPUTE229, could in principle perform better. 
However, in this work we focused on comparing different ML algorithms on a given unbiased dataset. As we show 
in the Results Section, strategy B3 is sufficient to this aim). For any given allele in the SNP we:
Unkw - leave the unknown values and treat them as a separate allele, or
Maj - substitute them with the most common allele, or
HW - substitute them with a random choice, following a binomial distribution that satisfy the Hardy-Weinberg 
equilibrium, for the controls (HWc), or for all samples (HWa).
Coding. The dataset is unphased, namely alleles in each SNP cannot be ordered for a given sample (phase infor-
mation does not seem to strongly improve the results in similar setups30). Therefore only 3 classes can be associ-
ated to each SNP. Different models can be considered, depending on the assumptions on these 3 classes. In the 
additive model, the SNP genotypes are ordered numbers: without loss of generality one can fix AA = 0, Aa = 1, 
aa = 2, implying that each additional number of copies of the minor allele increases the risk by the same amount. 
This coding method is referred as sum. A dominant model compares AA versus Aa + aa, and a recessive model 
compares AA + Aa versus aa, giving rise to only two effective classes (0 and 1). Finally, the three classes can be 
considered independently, if no strong assumptions can be made about dominance or additivity. This can be 
achieved in two different ways. The first option is to use a One-Hot Encoding on the three classes, giving rise 
to an effective number of 3*NSNP features in the dataset. We refer to this coding as the OHE coding. The second 
possibility is to keep the data as in its raw version (then called raw coding in the following), meaning considering 
each allele as an independent feature. It is easy to convince themselves that this is equivalent to consider the 3 
independent classes (0-0, 0-1, 1-1). The advantage of this second option with respect to the OHE model is that the 
number of effective features is now 2∗NSNP. In this paper, we focus on sum, OHE and raw coding. When interested 
to a not imputed dataset (referred above as Unkw), only categorical features make sense and OHE coding. Since 
in the Immunochip dataset the alleles for a given SNP are always either both known or both unknown, in this case 
one can code only the 4 classes 0-0, 0-1, 1-1, U-U (where U is an unknown allele).
Data separation, score, cross-validation. Samples have been randomly permuted, in order to obtain a similar 
case/control ratio on all subsets. Then the dataset has been separated in a Train dataset (34634 samples) and 
a Test dataset (17317 samples). In both Train and Test sets, the case/control ratio was around 0.53. We used 
the area under the ROC curve (AUC) as the score to evaluate the predictions of the different models. For all 
the models under study, to avoid over-fitting, we optimized the corresponding hyper-parameters by a 10-fold 
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cross-validation on the Train set (see details in the Supp. Info. text). We then evaluated on the Test set the models 
trained on the entire Train set.
SNPs preselection. Association analyses by comparing allele or genotype frequencies between cases and controls 
are widely used for GWAS. The most commonly used approach is indeed the single SNP scan, consisting in test-
ing each SNP sequentially with the null hypothesis of no association.
Different tests can be used in order to associate SNPs to the phenotype. For example, the additive genetic 
model can be tested using the Cochran-Armitage trend test31–33, which is equivalent to the score test in the LR34. 
Nevertheless, different contingency matrices and corresponding chi-squared test can be studied, depending on 
the genetic model taken into account.
ML algorithms can in principle deal with genome-wide SNPs. However, dataset with a large number of fea-
tures are subject to the curse of dimensionality. Therefore, a more efficient strategy consists in first reducing the 
total number of SNPs to a manageable level via a screening procedure, and look for causal loci among those 
passing a given threshold15,35,36.
In15 for example, a SNP preselection based on minimal allele frequency (MAF) threshold and p-values on 
single SNP association tests, is followed by a LR with Lasso regularization. Since in this case the aim is just to 
reduce the dimensionality of the space in which the data are embedded, less stringent thresholds than in associa-
tion studies are used. In this paper we used the threshold values > .MAF 0 01 and < −p 10 4, considered in15, as a 
benchmark point, and we studied the effects of changing them on the AUC score and on the feature selection at 
the level of SNPs and loci.
Moreover, in order to be as independent as possible from the assumptions of genetic models when selecting 
the panel of retained SNPs, we combined the results of different preselection methods. Namely, we kept the union 
of the SNP lists arising from chi-squared tests based on contingency matrices built on the independent classes 
model, on the dominant model, on a Cochran-Armitage trend test and on combined alleles counting. In the 
benchmark case, 120636 SNPs have MAF above the threshold, while 18381, 18200, 19176, and 20716 SNPs passed 
respectively the cut-off p-values of 10−4 for the tests mentioned above. Of those, 14606 lie in the intersections of 
these lists, while 21896 in the union, which is the final preselection we kept for this benchmark dataset.
Models and implementation. In this paper we considered three classes of models for case/control clas-
sification: logistic regression (LR), dense neural networks (NN) and gradient boosting on decision trees (GBT). 
Figure 1 shows a sketch of the different models strategies to associate a probability to a collection of input varia-
bles, in our case the probability of developing the disease starting from genotype data. All data and model analy-
ses have been performed in Python, with an extensive use of the library Scikit-learn37. All details concerning the 
parameters used in the different models can be found in the Supplementary Information text.
Logistic regression. In binary classification problems, LR is often the most natural choice to associate to each 
sample a probability to belong to one of the two classes. It is a particularly powerful model in the cases in which 
the log-odds of these probabilities only depend on a linear combination of the original features. Penalized (or 
Figure 1. Schematic representation of the machine learning models used in this paper for case/control 
classification. Colored circles represent input variables xi, yellow square the output prediction Y. Small wave 
symbol represents a sigmoidal function, used to transform a quantitative parameter into a probability of disease 
association. All formula are approximated and meant to give an idea of the models. (A) Logistic Regression: the 
prediction of this model is given by applying a sigmoid function to a weighted sum of the inputs. (B) Dense 
Neural Networks: they can be seen as multiple stacked logistic regressions. Here we represent a simplified 
network with one hidden layer with 3 neurons, and the output layer with 1 neuron. Each neuron receives the 
sigmoid of the weighted sum of its inputs. (C) Gradient Boosting on Decision Trees: the prediction is given by 
the sigmoid of the sum of the outputs leafs of hundreds of decision trees (η being the learning rate).
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regularized) LR imposes penalty terms to the logistic model in order to avoid the overfitting problem. In our anal-
ysis we considered Lasso (L1), Ridge (L2) and ElasticNet (combined L1 and L2) regularizations. All LR models 
have been implemented using Scikit-learn37.
Neural networks. Feed forward fully connected (dense) NN are a family of non-linear models that share in 
common a fully differentiable and layer-structured architecture. Depending on the number of hidden layers, the 
networks can be considered as shallow or as deep. From a mathematical point of view, one of the key ingredient 
that makes NN so efficient is their ability to integrate differentiable operations well suited to the structure of the 
data (convolution for images, recurrent units for time series, attention mechanisms for sequences etc.).
In this paper, we used some of the latest tools from deep learning, such as residual connections38, batch nor-
malization39, and dropout40, into fully connected NN.
In particular, we studied separately the cases:
•	 Dense NN with one fully connected hidden layer, but with a variable number of neurons.
•	 Dense NN with different numbers of fully connected hidden layers, all composed by 64 neurons.
•	 Dense NN with different odd numbers of fully connected hidden layers, all composed by 64 neurons, with 
full pre-activated residual blocks41
All models have been implemented in Python using the library Keras42 running on top of TensorFlow43.
Gradient boosting on decision trees. Boosting is a meta-algorithm based on the idea of gradually aggregating 
numbers of simple algorithms, called weak learners, to get a final strong learner44. More specifically, each weak 
learner is optimized to minimize the error on the training data using the sum of the previous weak learners pre-
dictions as an additional input.
Based on the seminal work of Friedman45 who introduced gradient boosting of decision trees (in fact CART 
trees), several implementations have been recently developed. In this paper, we compared the three most popular 
ones: XGBoost46, LightGBM47 and CatBoost48. While built on structurally similar ideas, these libraries slightly 
differ on how decision trees are grown or how categorical variables data are handled, and only experimentation 
can validate which performs best. To implement these models, we used the corresponding Python packages.
Random. In order to correctly identify the properties of the different models, we built a “random” model in 
which random weights are given to the preselected SNPs. In particular, this model allowed us to address the 
question of feature importance selection by taking into account biases related to the distribution of SNPs on the 
Immunochip. The AUC for this model was around 0.5 for any fold of the dataset.
SNP, loci and features importance selection. The large number of SNP markers and their not uni-
form distribution along the genome (see Supplementary Fig. S1), open the problem of categorizing them into 
functionally separated loci. Conventionally, signals from different markers are defined as coming from the same 
locus if the corresponding SNPs lie within a certain physical/genetic distance of each other. In order to simplify 
the analysis of the ordered lists of feature importance and based on the work by Jostins et al.3, we choose to define 
loci by globally partitioning the DNA in windows with sizes of 500 kb, which they prove to be a good trade-off 
between the need for functional independence of the genetic signals and the risk of splitting SNPs acting on the 
same gene in two independent loci. If two different SNPs lie in the same window, we consider them as belonging 
to the same locus.
We addressed the question of the important features selection. For each class of models we chose a par-
adigmatic one: Lasso penalized LR, a Residual Dense NN with 3 hidden layers of 64 neurons (ResDN3) and 
LightGBM (LGBM) for GBT. We then retained a criterion to assign a score of importance to each original feature 
(SNP).
Permutation feature importance (PFI) score is a widely used criterion: Random permutations on the samples 
have been performed at the level of each feature on the test set, worsening the AUC final score. The larger the 
deviation from the original AUC, the highest was the rank importance of the feature. For each features, the final 
score is obtained after averaging over the scores given by 10 different permutations. The main advantage of PFI 
score is that it can be universally used, independently on the ML model.
Moreover, in order to distinguish the dependence of the results on the model from that due to the criterion 
used to assign the ranking, we considered also a different criterion for LR and LGBM models. For LR we used the 
absolute value of the weight associated to each feature. The higher this value after training, the most important the 
corresponding feature was considered. For LGBM we used the ‘gain’ option already implemented in the library (it 
measures the average gain of the feature when it is used in trees).
A given model, with a fixed criterion, trained on different subsets of the data, give different results for the 
feature importance scores. To take into account this variability, for the second part of our analysis we created 10 
different folds: starting from the original whole dataset, we arbitrarily permuted 10 times the data and re-divided 
the dataset in Train and Test sets (with the same proportion of samples). For each model we then considered 10 
different lists of feature importance.
Since close SNPs can be considered as not independent, we compared the importance criteria of loci rather 
than of SNPs. To do that, we assigned a rank to the loci consisting of the highest score of the SNPs located in the 
genetic region. We then compared the predictions of the different models between them and with the loci identi-
fied by the meta-analysis of3 as associated to CD (called GWAS loci in the following). The score for these loci was 
assigned in the same way described above, by using the absolute value of the logarithm of OR.
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Notice that in Jostins et al.3, a locus was defined as a genetic region of 500 kb around the best associated SNP. 
The use of the same definition of locus was not possible in our study, because we wanted to compare different lists 
of feature importance. Loci defined in a relative way to the most important SNPs of each list would not allow a 
direct comparison between two different lists. On the other hand, with our absolute definition of loci, the compar-
ison between feature importance lists can suffer from boundary biases. In order to take into account these biases, 
and to smooth the comparison with the analysis of Jostins et al.3, we created a second partition (called bis) of the 
genome, shifted by 250 kb with respect to the original one. We then compared the two lists of SNPs coming from 
the two partitions (original vs original; bis vs bis and bis vs original).
Finally, the correlation between ranked lists was evaluated by a robustness measure introduced in49. The 
robustness is defined as:
=
Σ =R a
Mx (1)
i
x
i1
where M is the number of batches of data, and if Qi
x denotes the first x features in the feature ranking Qi produced 
by a feature selection algorithm using the i-th batch of data, the appearance times of each feature in the feature 
ranking matrix Qx are counted and for the top x appeared features, their appearance times are = …a i x, 1, 2, ,i .
We also used the Spearman rank test to evaluate the same correlation, and the results are shown in the 
Supplementary Information files.
Intra-model correlations were evaluated by computing the robustness R and Spearman rank correlation coef-
ficients rs associated to each couple of ranked lists produced by a given model on different folds. With 10 folds 
this gave rise to 45 rs values for each model. We thus computed the mean values and standard errors. Correlation 
between models has been evaluated by computing R and rs between ranked lists produced by two different models 
on the same fold (for a total of 10 different R and rs values).
Accession codes. Data have been deposited in the NCBI database of Genotypes and Phenotypes under 
accession numbers phs000130.v1.p1 and phs000345.v1.p1. Details about code and hyper-parameters are within 
the paper and its Supporting Information files. Feature importance analysis can be found at: https://github.com/
romagnoni/feat_imp_GWAS.git.
Results
We present here the results obtained by applying several ML classification methods to the IIBDGC Immunochip 
dataset, in terms of AUC scores and features selection after training. We first report the impact of QC and impu-
tation strategies on the performances of the classification algorithms, in the framework of Lasso LR. We then 
show the results obtained by the same linear models under different regularizations. Next, we describe the results 
obtained by powerful and popular algorithms, GBT and NN, shallow and deep. Finally, the comparisons between 
the best features identified by each method are reported.
Linear models. Different algorithms have been applied to the genotype/phenotype association problem in 
the literature. Besides the univariate models (based on the p-values on single SNP association tests), the simplest 
multivariate analyses use linear models in order to associate a phenotype to a genotype. LR is a common choice, 
usually coupled with Lasso regularization, after preselecting SNPs under mild constraints, as discussed in the 
Materials and Methods section. We compared this classical method with other linear models, in particular by 
changing the penalty in the regularization part of the cost function, and the preselection constraints.
Data pre-processing. We first studied the effect of different QC, imputation and coding strategies on AUC scores 
and on the selected predictor SNPs. To be able to compare the different analyses and evaluate the effects due to 
data pre-processing, we always applied the same algorithm, namely a LR with Lasso penalty, after SNP preselec-
tion as in the benchmark choice ( > .MAF 0 01 and < −p 10 4, see Materials and Methods). The results are shown 
in Table 1.
The unprocessed available dataset was associated with higher AUC values suggesting that artifacts may affect 
the results by inflating these values. The bias was likely related to the presence of missing genotypes which may 
reflect remaining stratification biases (data not shown). Indeed, imputing the values of the missing alleles using 
the HW method resulted in a large decrease of AUC values.
SNP preselection with more stringent QC criteria limited the impact of biases. Also in this case, the HW 
method was the best choice to limit the impact of missing genotypes. Notice that there was no major effect of 
genotype imputation using the allele frequencies derived from the whole dataset or healthy controls only.
Finally, the coding method also affected the results, the higher AUC values being observed for the sum method 
which consists in counting the number of rare alleles contributing to the genotype.
Interestingly, the number of retained SNPs in Lasso model depended on the processing method. While a 
stringent QC process did not affect significantly the number of retained SNPs, the sum coding method retained 
less SNPs for a better result, suggesting that it extracts more information from genotypes.
Qualitatively, the retained SNPs varied a lot according to the pre-processing method. This is expected because 
SNPs in strong linkage disequilibrium are interchangeable if they carry a shared information. We thus looked at 
the loci (defined by a regions of 500 kb, see Materials and Methods section) kept by the different models. The vast 
majority of the predictor loci are shared by the Lasso methods when performed on the QC dataset whatever the 
imputation and coding strategies (Table 1).
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The loci contributing to the Lasso model can be classified according to their respective weights. The best SNPs 
appeared often different from one model to another, whatever the data processing strategies and even for the same 
set of analyses. This finding argues for a large number of SNPs with comparable and low weights.
For homogeneity reasons, in the rest of the analysis we always used the QC/HWc/sum pre-processing strategy.
Feature and sample preselection. To explore the impact of SNP preselection, we next performed Lasso analyses 
on sets of SNP which passed at least one nominal association test with a p-value threshold ranging from 10−8 to 1 
(see Materials and Methods). The mean AUC value was not significantly affected when SNPs with p-values higher 
than 10−5 were discarded (Fig. 2A). However, even retaining only the most strongly associated SNPs (p-values 
lower than 10−8), the AUC remained higher than 0.78, despite the drastic decrease of predictors number. Indeed, 
the number of SNPs included in the linear model diminished from 6388 to 1702 when the threshold moved from 
1 to 10−8. This observation suggests that the linear model is mainly built with loci having the largest nominal 
effect. As a consequence, when the algorithm is fed with many additional loci with very small nominal effects it 
does not significantly improve its ability to classify patients and controls.
We also explored the impact of preselecting SNPs on their MAF. Despite an increasing number of preselected 
SNPs from 19763 to 26711 when the selection threshold on MAF decreased from 0.05 to 0.001, the values of the 
mean AUC did not significantly changed (Fig. 2B). This result suggests that very rare alleles do not carry a large 
effect in the model.
In the original dataset, the case-control ratio was 0.53. To explore the impact of this unbalanced ratio on the 
results of Lasso LR, we changed it with alternative values ranging from 0.53 to 1.5, by eliminating controls from 
the dataset. The results were slightly lower, arguing for keeping all the available samples in the analyses (Fig. 2C).
Due to these results, the rest of the analyses were performed on the set of all cases and controls and for prese-
lected SNPs with > .MAF 0 01 and association p-values lower than 10−4. The discarded features could in principle 
have a more important effect for non-linear models. Nonetheless, a similar analysis performed for the GBT algo-
rithm LightGBM shown that no significant improvement of the AUC score is obtained when relaxing the con-
straints on preselection p-values (Supplementary Fig. S2). Therefore, we made the choice to keep the same 
preselection conditions also for all non-linear models, for consistency and to alleviate the problems related to the 
curse of dimensionality.
Regularization. To explore the impact of alternative regularization methods, we analyzed the dataset with L2 
(Ridge) or mixed L1-L2 (ElasticNet) penalized regression methods (Fig. 2D). AUC values obtained with these 
methods were very similar to those of Lasso. However, the number of SNPs contributing to the retained models 
increased from 2575 (Lasso) to 4245 (Elastic net) and 21896 (Ridge). This finding suggests that the alternative 
methods were efficient to detect additional SNPs with very small effects but this property did not change the 
global result.
Non-linear models. Non linear methods are supposed to be more efficient in detecting non linear epistatic 
interactions between genotypes when compared to LR methods. We explored two main categories of non linear 
methods based on GBT and NN.
Neural networks. The simplest NNs are built with a single hidden layer composed of a variable number of neu-
rons. The mean AUC values obtained with mono-layer NN were in the same range as LR methods (Fig. 3A). 
Importantly, increasing the number of hidden neurons did not significantly increase the performance in classi-
fying patients and controls.
AUC train AUC test N pSNP NSNP≠0 ⁎ISNP
( ) ⁎ILoci
( ) ⁎ItopSNP
( ) ⁎ItopLoci
( ) ILoci
GWAS( ) ItopLoci
GWAS( )
NoQC/Unkw/OHE 0.925 ± 0.003 0.922 23583 2927 29% 55% 6% 35% 88% 19%
QC/Unkw/OHE 0.808 ± 0.008 0.802 21896 3198 69% 87% 38% 48% 89% 25%
NoQC/Maj/sum 0.901 ± 0.003 0.897 23583 3419 36% 69% 6% 23% 90% 12%
QC/Maj/sum 0.805 ± 0.008 0.800 21896 3553 91% 100% 64% 63% 91% 27%
NoQC/HWc/sum 0.812 ± 0.007 0.803 23583 2730 38% 66% 26% 45% 87% 29%
QC/HWc/sum 0.803 ± 0.008 0.800 21896 2575 — — — — 89% 36%
QC/HWc/OHE 0.796 ± 0.008 0.786 21896 3242 72% 89% 49% 60% 89% 29%
QC/HWc/raw 0.800 ± 0.008 0.792 21896 2757 72% 88% 57% 68% 89% 29%
QC/HWa/sum 0.803 ± 0.008 0.799 21896 2579 94% 99% 91% 96% 89% 36%
Table 1. Impact of Quality Control, Imputation of missing genotypes and Coding methods on the results of Lasso 
penalized Logistic Regression. Area Under Curve (AUC) obtained for 10-fold cross-validation on Train set and 
evaluation on the Test set, for Lasso penalized Logistic Regression applied to different combinations of QC/
imputation/coding choices (notations as in Materials and Methods section). The line with bold characters 
corresponds to our benchmark case (QC/HWc/sum). N pSNP indicate the number of preselected SNPs used as input 
of the model, ≠NSNP 0 is the number of SNPs associated with a nonzero coefficient. 
⁎ISNP
( )  and ⁎ILoci
( )  refer respectively to 
the percentage of SNP and loci (as defined in the main test) with associated non-zero coefficient, in common with 
the benchmark case. ⁎ItopSNP
( )  and ⁎ItopLoci
( )  columns show the same things for the corresponding 100 features with 
highest weight (in absolute value). ILoci
(GWAS) and ItopLoci
(GWAS) compare instead the same quantities to the list given in3.
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Inspired by the results obtained in multiple research fields by deep NN, we investigated the possibilities given 
by networks with multiple hidden layers (Fig. 3B). Despite the theoretically greater learning capacity of these 
architecture, multi-layers networks did not improve significantly the results.
It is well known though that training in deep networks can be problematic, since gradients tend to vanish 
in lower hidden layers. In order to take care of this problem, we implemented the idea of residual connection 
from38,41, which reduces the effect of vanishing gradients. We thus explored this more complex NN architecture, 
for different number of hidden layers (Fig. 3C). We obtained mean AUC values in the range of 0.80 also in this 
case.
Gradient boosting trees. GBT are a family of alternative methods proposed to go beyond linear additive models 
and take into account complex gene-gene interactions. We investigated three different state-of-the-art algorithms 
(XGBoost, LightGBM and CatBoost): As for NN, the mean AUC were in the range of 0.80 (Fig. 3D).
In summary, non linear methods did not appear more performant than linear ones arguing for limited 
epistatic effects in the genotyping dataset.
Combining the models. We investigated the possibility of combining different models in order to improve the 
performances. In particular we tried an ensemble method, which consists in training several classifiers and com-
bine their predictions to check if it can outperform any single classifier. In our case, when using the average as 
combination rule, by combining LR, ResDN3 and LGBM we obtained = . ± .AUC 0 810 0 007 on the 10-fold 
cross-validation, and = .AUC 0 802 on the test set, thus slightly improving the results obtained with a single 
model. This suggests that the different models can be seen as partially complementary. Very similar results are 
obtained when other models considered above are included in the ensemble approach.
Feature importance comparisons between methods. Comparisons with previous GWAS analy-
ses. The IIBDGC performed a large GWAS meta-analysis which included the Immunochip dataset3. As a result, 
an association at genome-wide significance ( < ⋅ −p 5 10 8) were retained for 140 independent CD loci (a locus 
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Figure 2. ROC AUC scores for Linear Regression model under different conditions on the dataset and on the 
penalty terms. Black dots and error bars refer to mean values and 2 standard deviation confidence intervals for 
10 fold cross-validated models on the train dataset. Red diamonds refer to AUC scores obtained on the test 
dataset with the model trained on the entire train dataset, using the corresponding cross validated hyper-
parameters. The numbers on top of the error bars refer to the number of features used by the model, and, in 
parenthesis, to the number of original features in the dataset. We show the AUC scores for: (A) different values 
of the upper bound on p-values for the SNP preselection phase, with > .MAF 0 01; (B) different values of the 
lower bound on MAF for the SNP preselection phase, with p-value < −p 10 4; (C) different values of the case/
control ratio; (D) different types of regularization. In (C,D) < −p 10 4 and > .MAF 0 01.
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was defined as a genetic region of 500 kb around the best associated SNP. In this paper we use a slightly different 
definition, see Materials and Methods) and the corresponding SNPs.
We compared the set of feature SNPs identified by Jostins et al. and those of three methods representative 
of the LR, NN and GBT approaches, respectively Lasso with weight as feature importance score, LGBM with 
gain and ResDN3 with PFI, as described in Materials and Methods. As shown in Fig. 4A, most of the SNPs with 
genomic nominal significance contributed to the architecture of the ML models: SNPs with the largest OR in the 
analysis of3 also correspond to a peak for LR, LGBM and ResDN3 methods. New regions seem to consistently 
contribute to the different models when more features are taken into account.
We further explored if the same common pattern can be recovered at the level of loci. Figure 4B indicates that 
near all the first best features of the LR, LGBM and ResDN3 were among the previously reported CD-associated 
loci as indicated by the value close to 1, near the origin, for the slope of the “intersection” curves. Notice that this 
was also partially the case for the random model, were SNPs were chosen at random among the preselected SNPs. 
This naively unexpected large number of loci in common with the other models may be explained by observing 
that the density of SNPs was much higher in CD-associated regions due to the strategy of SNP selection for the 
Immunochip (Supplementary Fig. S1).
Far from the origin though, the first more important SNPs for all models and more importantly for non-linear 
models like ResDN3 and LGBM, deviate from those by GWAS studies. Nonetheless, almost all CD-associated loci 
reported in the analysis of 3 appear in the best 800 loci for ML models, independently on the model and ranking 
criterion.
Robustness of the ML results. We next questioned the robustness of the ML methods in determining the impor-
tant features for this case/control classification problem. Therefore we looked at the robustness R of important loci 
arising by iterating the analyses using the same model trained on different folds of the data (Fig. 5A). A large pro-
portion of the first tens of loci were common to all the tests. However, the proportion of loci consistently selected 
as important, was higher for LGBM than for LR and ResDN3 between the first ~25 and ~100 loci. Nonetheless 
the opposite was true starting from ~250 loci. Very similar results were obtained when considering the Spearman 
coefficient rs (see Fig. S3 and discussion below). As expected, this proportion was significantly lower when SNPs 
were chosen at random.
As shown in the same Figure, the robustness through different batches of data was very similar for LGBM 
models with the two different criteria for feature selection (PFI and weight), while for LR the robustness for the 
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two criteria differed in a significant way once one considered more than ~75 first best loci. Nonetheless, when 
compared batch by batch, weight and PFI for the LR model were more robust than gain and PFI for the LGBM 
model for all x, x being the number of first best loci (Fig. 5B).
The comparison between models was also performed (Fig. 5C), when trained on the same fold of the dataset. 
As controls, we computed also the robustness between every model and the random choice of markers, and 
shown the mean results over the different results. Among between-methods comparisons, LR with PFI gives the 
more consistent ranking with LGBM with PFI for x 175 and with ResDN3 with PFI for x 175. On the other 
hand, ResDN3 provided features significantly more different from those of LR with weight and LGBM with gain. 
This observation suggests that either the measure used to weight the different loci in the NN models was not 
suitable, or the ResDN3 method was complementary to LR and/or LGBM.
Joint results. Because LR with weight, LGBM with gain and ResDN3 with PFI, could be seen as complementary, 
we looked at their joint results in terms of feature importance selection.
First, we looked at the loci simultaneously present within the first 140 most important of the three ML models, 
but absent in the GWAS meta-analysis. Two new loci were identified. rs35320439, located on chromosome 2 was 
in the vicinity of a gene coding for galactose-3-O-sulfotransferase 2 (GAL3ST2) which is over-expressed under 
TNFα stimulation in goblet cell-like in vitro50. rs395157 is located on chromosome 5, in the vicinity of a gene 
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Figure 4. Comparison of the best features selected from different linear and non-linear models and those 
associated to CD in the GWAS meta-analysis by Jostins et al.3 Panel A shows the importance and the position on 
the genome of the best 140 (left) and 800 (right) SNPs, selected by logistic regression with Lasso regularization 
and weight criterion (LR weight), LightGBM with gain criterion (LGBM gain), a dense residual neural network 
with 3 hidden layers with permutation feature importance criterion (ResDN3 PFI), and of those reported by 
Jostins et al.(GWAS). The importance of the SNPs is given by the criteria discussed in the main text, while for 
GWAS we show the log(OR) . Dotted vertical lines indicate the separation between chromosomes. Panel B 
shows the number of common loci (as defined in the main text) between the different models with different 
criteria for feature selection and GWAS analysis, as a function of the first x selected best loci. The random model 
was built using randomly weighted SNPs. Solid and dotted lines represent the mean values over all the subsets, 
while shaded regions represent the 1 standard deviation confidence intervals. The vertical dotted line indicates 
the 140 limit for GWAS, while the diagonal shows the perfect agreement baseline.
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coding for Oncostatin M receptor (OSMR). Recently, high pretreatment expression of Oncostatin M was associ-
ated with failure of anti-TNF therapy in IBD patients51. However, retrospectively, rs35320439 and rs395157 were 
found nominally associated with CD ( < −p 10 10) in the studied dataset with OR values of respectively 1.158 and 
1.141.
We then tested the robustness of a method able to integrate the results of two different models. We defined a 
list of importance features for combined methods by giving a rank to the loci in the following way. For each 
selected combination of models/feature selection criteria, we assigned a rank to a given locus accordingly to its 
order of appearance in the intersection between the ranked list of all considered models. We then evaluated their 
consistency throughout the training on different folds of the dataset. The mean values and standard errors are 
shown in Fig. 5D. Similarly to the results shown in Fig. 5A, when considered in combination with LR with PFI, 
the contribution of LGBM with PFI improved the consistency for ranking loci list of length between ~25 and 
~150, while that of ResDN3 for x 150.
Discussion
This work was devoted to compare the efficiency and the robustness of several ML methods.
The first part was devoted to the inspection of several technical aspects of data pre-processing which can affect 
the results of ML algorithms. As for statistical methods, QC constraints, imputing methods for missing genotypes 
and coding strategies for data analyses may affect the results of ML.
For LR methods, the very high AUC values obtained with the less stringent QC argue for a rigorous manage-
ment of the raw datasets. Nonetheless, imputing the missing genotypes is also a key factor and in our analysis ran-
dom imputation according to HWE corresponds to the most conservative case. Differences in these criteria may 
explain the discrepancies between this study and the previous report by Wei et al. who found a maximum AUC of 
0.86 with almost the same dataset but putatively with a less conservative constraints15. Similarly, using methods 
based on random forest algorithm, Botta et al. also analyzed the impact of QC on the results20. They obtained 
an AUC of 0.95 with weak QC pre-processing but only 0.76 with a more stringent pre-processing. Even if their 
impact appears less pronounced, coding strategies may also affect the results of ML algorithms, the summation of 
the number of minor alleles being the most efficient in our analysis.
As an added proof for these results, we initially used a different dataset, with less stringent choices for the QC 
and imputation strategy. The AUC for Lasso LR was artificially inflated to 0.85 but interestingly, GBT methods 
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Figure 5. Internal and between-models coherence in feature importance selection. We show the robustness R 
as a function of the first x best loci. In panel (A) we consider the robustness of a given model/criterion, when 
trained on two different subsets of the data. In panel (B) we show the robustness between the same model when 
two different criteria are considered on the same subset of the dataset. In panel (C) we compare two different 
models/criteria, on the same subset of the dataset. Finally in panel (D) we show the same analysis of panel (A) 
for combination of models. Solid and dotted lines represent the mean values of the robustness distributions, 
respectively in panels (A and D) over all the couples of subsets (10 subsets, for a total of 45 couples), and in 
panels (B,C) over all the subsets (10 subsets, for a total of 10 couples). Shaded regions represent the 1 standard 
deviation confidence intervals.
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outperformed these results, by 2% on this dataset. In regards to the results obtained later with more rigorous QC 
choices, we made the hypothesis that GBT better exploit the biased information hidden in missing values. In con-
clusion and not surprisingly, this analysis confirms that QC, imputing and coding methods have to be taken into 
account when comparing the results obtained by different groups and different methods.
For this study, we used the Immunochip dataset built through the international consortium for IBD genetics. 
Our choice was motivated by the fact that this dataset contains three fold more cases than the largest GWAS dataset 
available for CD. However, the Immunochip panel of markers is a less homogeneous representation of the genome 
than a GWAS panel. Chen et al. estimated that about 25% of the SNP heritability that is tagged in the GWAS data is 
lost using the ImmunoChip52. It can thus be imagined that some key SNPs, somewhere in the genome, common or 
rare, may have not been tested. However, the Immunochip panel has been built to include all the common genetic 
variants with nominal p-values < −p 10 4 in previous GWAS analyses. Thus, it is supposed to contain the majority 
of common CD-associated SNPs. Considering that there is no example of a genetic variant with no nominal asso-
ciations and with a strong effect discovered by ML algorithms, it seems unlikely that a larger panel would increase a 
lot the maximum AUC values. The results obtained with variable preselection thresholds on p-values and MAF also 
argue against putative common or rare alleles unavailable in the dataset but playing a key role in the genetic archi-
tecture of CD. Nonetheless the co-occurrence of numerous small epistatic effects cannot be excluded a priori and 
an in-depth analysis on GWAS-like datasets will be compelling in the future to confirm or exclude this possibility.
Even if we explored a large panel of ML methods, a limitation of the study is that it is based on a finite number 
of algorithms. Indeed, by definition, not all possible algorithms can be tested by a group alone and one could 
always wonder if an alternative approach could be more efficient. To tackle this question, we explored the wisdom 
of the crowd idea. 73 graduate students worked independently on the partial and biased dataset mentioned above, 
where names and position of SNPs and disease trait were hidden to obfuscate the data. Top performers used GBT 
methods, obtaining our same score values. Overall, this exercise can be seen as an external confirmation of the 
robustness of the results presented in this paper.
Consistently with GWAS analyses, the different ML methods recognized the CD-associated loci with the 
best nominal p-values among their best predictors. Although we identified two new CD-associated genes with 
ML methods, it appears that retrospectively, they could have been detected by classic statistical approaches. This 
observation thus argues against the presence of loci with no nominal effect but major effect in the classification 
problem. In addition to the known CD-associated loci, ML models take into account many additional SNPs with 
low effect. These numerous genetic variants likely carry similar impact on the classification performance as shown 
by their interchangeability within and between models. As a whole, these findings do not argue for large epistatic 
effects in the genetic architecture of the disease.
While deep learning methods have proved to be extremely efficient on unstructured signal data (images, 
sound, text, time-series etc.), boosting methods using decision trees as weak learners remain the non-linear 
default algorithm used by ML practitioners for any other type of data. On our data the different ML methods 
have similar power to classify patients and controls. Also, when comparing the robustness for the lists of the most 
important loci for the different models, when trained and tested on different batches of the data, no model proved 
itself consistently better than the others. For lists of 25–75 best loci, GBM methods appear to be more robust, 
while LR and NN should be chosen for longer lists. As discussed in a large part of the literature, the choice of 
the feature importance criterium play an important role and permutation feature importance seem to be more 
suitable for the problem we investigated.
Under stringent QC constraints, the maximum AUC values obtained by LR, GBT or NN are in the range of 
0.80. For comparison, AUC of 0.75 and 0.99 have been proposed as relevant thresholds for diagnostic classifiers 
clinically useful when applied respectively to at-risk people or to the general population2. More importantly, these 
modest AUC values contrast with the expected ones. Theoretical works have shown that for a complex genetic 
disorder with a strong heritability and a low prevalence like CD, a genomic profile would be able to reach an AUC 
close to 12. Even if the variants included in the genomic profile explain only 1/4 of the known genetic variance, the 
AUC is expected to be as high as 0.862. The incapacity of ML methods to reach this value could indicate that the 
ability to classify diseased people may not be accessible with the genetic information alone. On the other hand, in 
our study, the specific design of the Immunochip could have withdrawn from the very beginning SNPs respon-
sible for nonlinear epistatic effects. In order to have a more accurate evaluation of the quantity of information 
about the disease which is contained in the genome, similar studies should also be performed on larger dataset, 
like GWAS, if provided with a sufficient cohort. Nonetheless, the incorporation of environmental parameters and/
or phenotypic information like RNA levels or protein functions in ML methods could also be necessary to reach 
the goal of disease prediction.
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